Salazar F et al. |
Renal effects induced by prolonged mPGES1 inhibition. |
2014 |
Am. J. Physiol. Renal Physiol. |
pmid:24197070
|
Kawai VK et al. |
Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome. |
2014 |
Arthritis Care Res (Hoboken) |
pmid:24022862
|
Elsheikh W et al. |
Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer. |
2014 |
Nitric Oxide |
pmid:24747869
|
Suarez-Kurtz G |
Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of oxicam NSAIDs. |
2014 |
Pharmacogenet. Genomics |
pmid:25003537
|
Lee HI et al. |
Response to Suarez-Kurtz's comments on strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. |
2014 |
Pharmacogenet. Genomics |
pmid:25003538
|
Shan MQ et al. |
[Comparative study on effects of Rubiae Radix et Rhizoma and carbonized Rubiae Radix et Rhizoma on acute blood stasis rat model]. |
2014 |
Zhongguo Zhong Yao Za Zhi |
pmid:24946554
|
Zhou K et al. |
A CAPE analogue as novel antiplatelet agent efficiently inhibits collagen-induced platelet aggregation. |
2014 |
Pharmazie |
pmid:25158573
|
Lee HI et al. |
Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. |
2014 |
Pharmacogenet. Genomics |
pmid:24322170
|
Voisin V et al. |
Protection of Wistar-Furth rats against postischaemic acute renal injury: role for nitric oxide and thromboxane? |
2014 |
Clin. Exp. Pharmacol. Physiol. |
pmid:25115485
|
Zhu Y et al. |
Effects and mechanisms of Fenofibrate on the secretion of vascular endothelial contraction factors in hypertensive rats. |
2014 |
Genet. Mol. Res. |
pmid:25078582
|
Hong S et al. |
Maresin-like lipid mediators are produced by leukocytes and platelets and rescue reparative function of diabetes-impaired macrophages. |
2014 |
Chem. Biol. |
pmid:25200603
|
Tong B et al. |
[Atorvastatin inhibits platelet aggregation and activation following carotid balloon injury in cholesterol-fed rabbits]. |
2014 |
Nan Fang Yi Ke Da Xue Xue Bao |
pmid:25176087
|
Kaplon-Cieslicka A et al. |
Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study. |
2014 |
Cardiovasc Diabetol |
pmid:25123549
|
Hayashi G et al. |
Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia. |
2014 |
Hum. Mol. Genet. |
pmid:25104852
|
Floyd CN et al. |
Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. |
2014 |
Br J Clin Pharmacol |
pmid:25099258
|
Zhu SH et al. |
Protective effect of indomethacin in renal ischemia-reperfusion injury in mice. |
2014 |
J Zhejiang Univ Sci B |
pmid:25091992
|
Basili S et al. |
Aspirin reload before elective percutaneous coronary intervention: impact on serum thromboxane b2 and myocardial reperfusion indexes. |
2014 |
Circ Cardiovasc Interv |
pmid:25074252
|
Lattanzio S et al. |
Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin. |
2014 |
J Am Heart Assoc |
pmid:25037197
|
Santilli F et al. |
Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. |
2014 |
J Am Heart Assoc |
pmid:25037196
|
Patrignani P et al. |
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. |
2014 |
J. Thromb. Haemost. |
pmid:24942808
|